(MENAFN- Investor Ideas) Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September:
Paid News Dissemination of behalf of AEMD.
September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this conference, hosted by virtualinvestorconferences , on Thursday, September 19, 2024 at 1:30 pm ET. Management will also be available for one-on-one meetings on September 19 and 20, 2024.
Interested investors can pre-register for the conference using this link , which will be a live interactive online event where investors can ask the company questions in real-time. An archived webcast will also be available after the event.
September 25: Virtual Emerging Growth Conference: Mr. Frakes and Dr. LaRosa will present a company overview at this conference on Wednesday, September 25, 2024 at 12:35 pm ET.
After the presentation, management will open the floor for questions. Investors may submit questions in advance to ... or ask questions during the event.
Please register using this link to attend the virtual conference and receive any updates that are released.
An archived webcast will also be made available on and on the Emerging Growth YouTube Channel, , which will be released after the event.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at .
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
...
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
...
917-513-5303
SOURCE Aethlon Medical, Inc.
Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas
More info on AEMD at Investorideas Visit:
Get News Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured tech stock on Investor ideas More disclosure: Contact management and IR of each company directly regarding specific questions.
More disclaimer info: Learn more about publishing your news release and our other news services on the Investorideas newswire and tickertagstocknews
Global investors must adhere to regulations of each country.
MENAFN17092024000142011025ID1108684682
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.